Topiramate Capsule, Extended Release
Product Images NDC 0832-1073

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 0832-1073). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Topiramate 01)

Chemical structure of the active ingredient Topiramate, shown as a molecular diagram with atoms and bonds illustrating its chemical composition.*

FDA Label Image

Figure 1 (Topiramare 02)

A Kaplan-Meier cumulative rate graph showing time to first seizure over 500 days for patients taking Topiramate at 50 mg/day and 400 mg/day doses. The y-axis represents cumulative rates for time to first seizure, while the x-axis shows time in days. Two lines compare seizure occurrence between the two dosing groups with a p-value of 0.0002 indicated.*

FDA Label Image

Figure 2 (Topiramate 03)

A bar chart displaying the proportion of patients (%) versus reduction in seizure frequency from baseline (%). It compares placebo and Topiramate Extended-Release Capsules 200 mg/day across groups with different seizure reduction ranges (Worse, 0-<25, 25-<50, 50-<75, 75-100). Black bars represent Topiramate and white bars represent placebo.*

FDA Label Image

Figure 3 (Topiramate 04)

A bar chart comparing the change from baseline to double-blind phase in average monthly migraine period rate (MPR) for placebo and Topiramate doses 50 mg/day, 100 mg/day, and 200 mg/day, based on two studies. The chart shows mean reductions with error bars for each group, with statistically significant decreases at higher doses indicated by asterisks.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

Topiramate Extended Release Capsules 25 mg strength in a pack of 30 capsules. The label indicates once-daily dosing, includes storage instructions, and states the product is for oral use. Manufactured and distributed by Upsher-Smith Laboratories, LLC.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Label for Topiramate Extended-Release Capsules, 50 mg strength, in a package containing 30 capsules. The label includes directions for pharmacists to dispense the medication guide separately. It provides dosage form as extended-release capsules for oral use, with manufacturer information for Upsher-Smith Laboratories, LLC.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

Label for Topiramate Extended-Release Capsules 100 mg, oral dosage form by Upsher-Smith Laboratories, LLC. The label indicates 30 capsules per package, once-daily dosing, and includes storage and handling instructions, plus manufacturer information. The label also features a barcode and an NDC number.*

FDA Label Image

Principal Display Panel (150 mg Capsule Bottle Label)

Label for Topiramate Extended-Release Capsules 150 mg by Upsher-Smith Laboratories, LLC. The label includes dosage instructions for once-daily oral administration, child-resistant packaging storage conditions, and a package quantity of 30 capsules. The product is manufactured for Upsher-Smith Laboratories and the label states it is a prescription drug.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

Label for Topiramate Extended-Release Capsules 200 mg by Upsher-Smith Laboratories, LLC. The label indicates once-daily dosing and contains 30 capsules. It includes storage instructions, manufacturer details, and a barcode. The medication is prescription-only and child-resistant packaging is noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.